Arctic Bioscience AS (OSL:ABS) Cash-to-Debt : 14.06 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Arctic Bioscience AS's cash to debt ratio for the quarter that ended in Dec. 2023 was 14.06.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Arctic Bioscience AS could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Arctic Bioscience AS's Cash-to-Debt or its related term are showing as below:

OSL:ABS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 8.59 Max: 176.85
Current: 14.06

During the past 6 years, Arctic Bioscience AS's highest Cash to Debt Ratio was 176.85. The lowest was 0.03. And the median was 8.59.

OSL:ABS's Cash-to-Debt is ranked better than
60.71% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs OSL:ABS: 14.06

Arctic Bioscience AS Cash-to-Debt Historical Data

The historical data trend for Arctic Bioscience AS's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Arctic Bioscience AS Cash-to-Debt Chart

Arctic Bioscience AS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

3.11

1.23

176.85

130.50

14.06

Arctic Bioscience AS Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial					176.85	No Debt	130.50	27.14	14.06

Competitive Comparison of Arctic Bioscience AS's Cash-to-Debt

For the Biotechnology subindustry, Arctic Bioscience AS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arctic Bioscience AS's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Arctic Bioscience AS's Cash-to-Debt falls into.

Arctic Bioscience AS Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Arctic Bioscience AS's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	78.471	/	(3.531	+	2.049)
	=	14.06

Arctic Bioscience AS's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	78.471	/	(3.531	+	2.049)
	=	14.06

Arctic Bioscience AS (OSL:ABS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Arctic Bioscience AS Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Arctic Bioscience AS's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Arctic Bioscience AS (OSL:ABS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Industrivegen 42, Orsta, NOR, 6155

Website

https://www.arctic-bioscience.com

Arctic Bioscience AS is a Norwegian biotechnology company. The company is focused on developing products and solutions based on bioactive marine compounds. The product portfolio includes nutraceuticals and pharmaceuticals. It is currently developing a novel, cost-efficient oral treatment (HRO350) for mild-to-moderate psoriasis. Its nutraceutical products are sold globally to both B2C and B2B under the Romega brand.

Arctic Bioscience AS (OSL:ABS) Headlines

No Headlines